Search Within

Wungki Park

  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (53)
  2. Journal Article (34)
  3. Review (5)
  4. Correspondence (3)
  5. Editorial (3)
Groups
  1. CTCR Scholars (98)
  2. Center for Pancreatic Cancer Research (98)
  3. Department of Medicine (98)
  4. Gastrointestinal Oncology Service (98)
  5. MSK Grad Students (98)
  6. Master of Science in Clinical and Translational Cancer Research (98)

More Groups

People
  1. Eileen O'Reilly (72)
  2. Anna Varghese (37)
  3. Kenneth Yu (33)
  4. Joanne Chou (25)
  5. William Jarnagin (25)
  6. Alice Wei (23)

More People

Years
  1. 2025 (7)
  2. 2024 (27)
  3. 2023 (18)
  4. 2022 (12)
  5. 2021 (11)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal for ImmunoTherapy of Cancer (9)
  3. Annals of Surgical Oncology (5)
  4. Annals of Oncology (4)
  5. JCO Precision Oncology (4)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (39)
  2. Biomed Central Ltd (9)
  3. Oxford University Press (7)
  4. Springer (7)
  5. Elsevier Inc. (5)
  6. Nature Publishing Group (5)

More Publishers

Results (98)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Extended mutational profiling by MSK-IMPACT™ identifies mutations predicting thromboembolic risk in patients with solid tumor malignancy
    Meeting Abstract

    Dunbar, A.; Bolton, K.; Devlin, S. M.; Sanchez-Vega, F.; Gao, J.; Mones, J. V.; Wills, J. M.; Kelly, D.; Farina, M.; Kishore, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC)
    Meeting Abstract

    Bendell, J.; Rasco, D.; Park, W.; Zhou, L.; Galkin, A.; Slee, D.; Carter, L.; Nickle, D.; Tran, R.; Li, J.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Park, W.; Wong, W.; Yu, K. H.; Varghese, A. M.; Riaz, N.; Balachandran, V. P.; El Dika, I. H.; Raj, N. P.; Khalil, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis
    Meeting Abstract

    Florou, V.; Park, W.; Hosein, P. J.; Wilky, B. A.; Trent, J. C.; Lopes, G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Toward a comprehensive view of cancer immune responsiveness: A synopsis from the SITC workshop
    Review

    Bedognetti, D.; Ceccarelli, M.; Galluzzi, L.; Lu, R.; Palucka, K.; Samayoa, J.; Spranger, S.; Warren, S.; Wong, K. K.; Ziv, E.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Perspectives: Neutrophil-to-lymphocyte ratio as a potential biomarker in immune checkpoint inhibitor for non–small-cell lung cancer
    Editorial

    Park, W.; Lopes, G.
    Clinical Lung Cancer (2019)

    Fulltext@MSK | Save
  • Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review
    Review

    Singh, R. R.; Goldberg, J.; Varghese, A. M.; Yu, K. H.; Park, W.; O'Reilly, E. M.
    Cancer Treatment Reviews (2019)

    Fulltext@MSK | Save
  • Frameshift indel selectively correlates with immunotherapy outcome for advanced NSCLC
    Meeting Abstract

    Park, W.; Park, L. C.; Florou, V.; Saravia, D.; Chang, S.; Wang, S.; Chiec, L.; Rahbari, A.; Viveiros, P.; Sukhadia, B.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save